Alzheimer’s Blood Tests: What They Can—and Cannot—Tell

How can a blood test help assess Alzheimer’s disease?

Alzheimer’s disease is associated with changes in amyloid and tau proteins in the brain. Some of these changes can be reflected in blood-based biomarkers, which researchers are studying as less invasive tools to support assessment of people with cognitive symptoms. A blood test may help inform the next step in an evaluation, but it does not replace a detailed history, cognitive assessment, or review of other possible causes of memory problems.

Test performance depends on the particular assay, the population being tested, and the clinical question. A result should therefore be interpreted by a qualified clinician alongside symptoms, medical history, and other findings. Depending on the situation, additional testing—such as brain imaging or cerebrospinal fluid analysis—may still be considered to clarify the diagnosis.

Can a blood test determine whether someone should receive Alzheimer’s treatment?

Some newer Alzheimer’s treatments are intended for people at an early stage of disease and target amyloid in the brain. Before treatment is considered, clinicians need to establish that the patient’s symptoms and disease stage fit the treatment’s intended use and assess potential risks. A blood test may help guide that process, but it should not be treated as a stand-alone prescription decision.

For patients and families, the practical value of testing depends on whether the result leads to a clearer diagnosis or changes care. A clinician can explain what a specific test measures, how reliable it is for the patient’s situation, and whether confirmatory testing is needed. People concerned about memory or thinking changes should seek a medical evaluation rather than relying on an isolated test result.